Chen Hsin-Chien, Liang Chang-Min, Wang Chih-Hung, Huang Ming-Yuan, Lin Yuan-Yung, Shih Cheng-Ping, Kuo Chao-Yin, Lin Yi-Chun, Chen Hang-Kang
Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan.
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan; Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Center, Taipei, 114, Taiwan.
Int J Pediatr Otorhinolaryngol. 2019 Feb;117:67-72. doi: 10.1016/j.ijporl.2018.11.018. Epub 2018 Nov 15.
To develop a surgical approach for cell transplantation into mouse cochlear nerves via an intracranial route and investigate whether transplantation of human limbus-derived mesenchymal stromal cells (HL-MSCs) can improve hearing in this model of auditory neuropathy.
We used 8-week-old CBA/CaJ male mice and created ouabain-induced auditory neuropathy. The surgical approach passed through the cerebellum to reveal the superior semicircular canal and brainstem, allowing access to the auditory nerve. Then HL-MSCs were injected around the cochlear nerve trunk using a micropipette driven by a micropump. Hearing thresholds in the mice were determined by auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs).
We produced ouabain-induced neuropathy in mice with an elevated hearing threshold but normal DPOAE. Using immunohistological staining, we detected HL-MSCs were localized in the cochlear nerve trunk 2 days after cell transplantation via this occipital approach. More spiral ganglion neurons were detected in ouabain-treated cochleae 3 months after HL-MSCs transplantation compared to those without HL-MSCs transplantation. The ABR showed significant hearing improvement 3 months after HL-MSCs transplantation.
We successfully established a mouse model for cell transplantation into the intracranial cochlear nerve trunk and showed that HL-MSCs potentially can be applied as cell therapy to treat sensorineural hearing loss.
开发一种通过颅内途径将细胞移植到小鼠耳蜗神经的手术方法,并研究人角膜缘间充质基质细胞(HL-MSCs)移植是否能改善这种听觉神经病变模型中的听力。
我们使用8周龄的CBA/CaJ雄性小鼠,制造哇巴因诱导的听觉神经病变。手术路径穿过小脑以暴露上半规管和脑干,从而能够接近听神经。然后使用由微量泵驱动的微量移液器将HL-MSCs注射到耳蜗神经干周围。通过听性脑干反应(ABR)和畸变产物耳声发射(DPOAE)测定小鼠的听力阈值。
我们在小鼠中制造了哇巴因诱导的神经病变,其听力阈值升高但DPOAE正常。使用免疫组织化学染色,我们发现在通过这种枕部途径进行细胞移植后2天,HL-MSCs定位于耳蜗神经干。与未进行HL-MSCs移植的小鼠相比,在HL-MSCs移植后3个月,在哇巴因处理的耳蜗中检测到更多的螺旋神经节神经元。HL-MSCs移植后3个月,ABR显示听力有显著改善。
我们成功建立了一种将细胞移植到颅内耳蜗神经干的小鼠模型,并表明HL-MSCs有可能作为细胞疗法用于治疗感音神经性听力损失。